<DOC>
	<DOCNO>NCT01733238</DOCNO>
	<brief_summary>This study sponsor Sierra Oncology , Inc. formerly ProNAi Therapeutics , Inc . It study multi-center , nonrandomized , open-label , pilot Phase II investigation PNT2258 characterize anti-tumor activity collect safety data patient relapse refractory lymphoma .</brief_summary>
	<brief_title>Study PNT2258 Treatment Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>PNT2258 administer dose 120 mg/m2 , 3-hour intravenous ( IV ) infusion day 1-5 21-day cycle . Treatment may continue ( unless disease progression occurrence unacceptable toxicity ) total 6 cycle therapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>1 . Written informed consent must obtain patient . 2 . Participants must ≥18 year age . 3 . Morphologically confirm diagnosis nonHodgkin 's lymphoma ( NHL ) . 4 . At least single measureable tumor mass ( long axis &gt; 1.5 cm ) . 5 . An FDGPET positive baseline scan . . A positive scan define per revise Cheson criterion `` focal diffuse FDG uptake background location incompatible normal anatomy physiology , without specific standardized uptake value cutoff '' . 6 . Disease relapse administration primary therapy include : 1 . Rituximab 2 . CHOP , EPOCH , bendamustine similar chemotherapy subsequent salvage regimen . Note : Relapse define progression complete response therapy radiographic evidence active disease partial response stable disease . 7 . Have receive three few complete course systemic cytotoxic regimen . Note : Rituximab ( alone combination cytotoxic chemotherapy ) consider cytotoxic regimen . 8 . No previous exposure PNT2258 . 9 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 10 . Have discontinue prior anticancer therapy least 21 day ; biologic therapy least 4 halflives drug ( ) ; radioimmunotherapy ( 10 week ) ; autologous stem cell transplantation ( SCT ) ( 3 month ) must stable baseline regard acute toxicity associate prior therapy . 11 . Adequate organ function include : 1 . Hematologic Function : absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L prior treatment . Platelets ≥ 100 x 109/L . 2 . Hepatic : Total Bilirubin ≤ 1.5 x ULN serum transaminase level ≤ 2.5 x upper limit normal ( ULN ) . 3 . Renal : Serum creatinine ≤2 x ULN creatinine clearance ≥ 60 mL/min/1.73 m2 subject serum creatinine level 2x ULN . 1 . Candidates HDT autologous SCT . Note : Patients progress &gt; 3 month highdose therapy ( HDT ) /SCT eligible . 2 . Concurrent malignancy require treatment . 3 . Symptomatic central nervous system ( CNS ) leptomeningeal involvement lymphoma . 4 . Concurrent serious medical condition ( determine Principal Investigator ) include , limited , HIVassociated lymphoma ; active bacterial , fungal viral infection . 5 . Signs symptoms heart failure characterize great New York Heart Association ( NYHA ) Class I . 6 . History myocardial infarct prolong correct QT ( QTc ) interval ( &gt; 450 millisecond ( msec ) males &gt; 470 msec female ) significant cardiac abnormality . 7 . Women pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PNT2258</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>NHL</keyword>
</DOC>